RxDoctor Payments Data

Denis Ruiz Serrano, MD

Cardiovascular Disease · Guaynabo, PRNPI 1508835869

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $48,550 of the $65,849 with a category attached, or 73.7%. Johnson & Johnson accounts for 83.2% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $39,817 and has fallen 96.3% since, to $1,489 in 2025. Among cardiovascular disease clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,849in general payments, 2019–2025

Across 452 payments — averaging $145.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$55K
  • Boehringer Ingelheim$2K
  • Boston Scientific$1K
  • AstraZeneca$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$1K
  • plus $4K from 13 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$48,55074%
  • Travel & lodging$1,8363%
  • Food & beverage$15,13023%
  • Education$330%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson129$54,777
Boehringer Ingelheim57$2,383
Boston Scientific17$1,407
AstraZeneca56$1,292
E.r. Squibb & Sons, L.L.C.53$1,215
Amgen33$1,128
PBG Puerto Rico LLC46$1,058
Abbott8$655
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)17$525
Medtronic(2 entities)4$467
Merck14$380
Scpharmaceuticals Inc.3$160
Novartis6$140
Edwards Lifesciences2$138
Bayer Puerto Rico Inc.2$48
Bayer1$25
Pfizer Pharmaceuticals LLC1$23
Sanofi-aventis U.S. LLC1$20
Pfizer2$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,849 in reported general payments places this provider in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$10,637
Medicare patients
39
Services billed
124

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban723$556,850
EntrestoSacubitril/Valsartan411$328,702
XareltoRivaroxaban354$253,405
FarxigaDapagliflozin Propanediol314$245,149
JardianceEmpagliflozin284$217,725
Repatha SureclickEvolocumab154$92,832
Atorvastatin Calcium3,604$48,351
Metoprolol Succinate1,960$37,921
Ezetimibe1,551$33,217
Losartan Potassium2,105$25,754
Rosuvastatin Calcium1,324$22,414
Candesartan Cilexetil168$18,685
Hydralazine Hcl834$16,733
Repatha SyringeEvolocumab29$16,468
SynjardyEmpagliflozin/Metformin Hcl11$13,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$9$556,850723 claims
NovartisEntresto$140$328,702411 claims
AstraZenecaFarxiga, Brilinta$1,292$258,643330 claims
Johnson & JohnsonXarelto$54,777$253,405354 claims
Boehringer IngelheimJardiance, Synjardy$2,383$231,656295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Guaynabo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →